SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Patrick G. N.) srt2:(2015-2019)"

Sökning: WFRF:(Patrick G. N.) > (2015-2019)

  • Resultat 1-10 av 82
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  • Ruilope, LM, et al. (författare)
  • Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
  • 2019
  • Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
  • Tidskriftsartikel (refereegranskat)abstract
    • <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  • 2019
  • Tidskriftsartikel (refereegranskat)
  •  
9.
  •  
10.
  • Loza, M. J., et al. (författare)
  • Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study
  • 2016
  • Ingår i: Respiratory Research. - : Springer Nature. - 1465-9921 .- 1465-993X. ; 17:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Asthma is a disease of varying severity and differing disease mechanisms. To date, studies aimed at stratifying asthma into clinically useful phenotypes have produced a number of phenotypes that have yet to be assessed for stability and to be validated in independent cohorts. The aim of this study was to define and validate, for the first time ever, clinically driven asthma phenotypes using two independent, severe asthma cohorts: ADEPT and U-BIOPRED. Methods: Fuzzy partition-around-medoid clustering was performed on pre-specified data from the ADEPT participants (n = 156) and independently on data from a subset of U-BIOPRED asthma participants (n = 82) for whom the same variables were available. Models for cluster classification probabilities were derived and applied to the 12-month longitudinal ADEPT data and to a larger subset of the U-BIOPRED asthma dataset (n = 397). High and low type-2 inflammation phenotypes were defined as high or low Th2 activity, indicated by endobronchial biopsies gene expression changes downstream of IL-4 or IL-13. Results: Four phenotypes were identified in the ADEPT (training) cohort, with distinct clinical and biomarker profiles. Phenotype 1 was "mild, good lung function, early onset", with a low-inflammatory, predominantly Type-2, phenotype. Phenotype 2 had a "moderate, hyper-responsive, eosinophilic" phenotype, with moderate asthma control, mild airflow obstruction and predominant Type-2 inflammation. Phenotype 3 had a "mixed severity, predominantly fixed obstructive, non-eosinophilic and neutrophilic" phenotype, with moderate asthma control and low Type-2 inflammation. Phenotype 4 had a "severe uncontrolled, severe reversible obstruction, mixed granulocytic" phenotype, with moderate Type-2 inflammation. These phenotypes had good longitudinal stability in the ADEPT cohort. They were reproduced and demonstrated high classification probability in two subsets of the U-BIOPRED asthma cohort. Conclusions: Focusing on the biology of the four clinical independently-validated easy-to-assess ADEPT asthma phenotypes will help understanding the unmet need and will aid in developing tailored therapies. Trial registration:NCT01274507(ADEPT), registered October 28, 2010 and NCT01982162(U-BIOPRED), registered October 30, 2013.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 82
Typ av publikation
tidskriftsartikel (81)
rapport (1)
Typ av innehåll
refereegranskat (78)
övrigt vetenskapligt/konstnärligt (4)
Författare/redaktör
Kasaeian, Amir (15)
Qorbani, Mostafa (15)
Brenner, Hermann (14)
Jonas, Jost B. (14)
Alkerwi, Ala'a (14)
Geleijnse, Johanna M ... (13)
visa fler...
Khang, Young-Ho (13)
Sepanlou, Sadaf G. (13)
Shiri, Rahman (13)
Topor-Madry, Roman (13)
Khader, Yousef Saleh (12)
Lotufo, Paulo A. (12)
Malekzadeh, Reza (12)
Farzadfar, Farshad (11)
Djalalinia, Shirin (11)
Bhutta, Zulfiqar A. (11)
Cooper, Cyrus (10)
Mokdad, Ali H. (10)
Nagel, Gabriele (10)
Naghavi, Mohsen (10)
Sartorius, Benn (10)
Uthman, Olalekan A. (10)
Vos, Theo (10)
Werdecker, Andrea (10)
Yonemoto, Naohiro (10)
Murray, Christopher ... (10)
Majeed, Azeem (10)
Hofman, Albert (10)
Shibuya, Kenji (10)
Larsson, Anders (9)
McKee, Martin (9)
Hay, Simon I. (9)
Afshin, Ashkan (9)
Esteghamati, Alireza (9)
Hamidi, Samer (9)
Mendoza, Walter (9)
Miller, Ted R. (9)
Rai, Rajesh Kumar (9)
Roshandel, Gholamrez ... (9)
Tran, Bach Xuan (9)
Al-Aly, Ziyad (9)
Bennett, Derrick A. (9)
Hafezi-Nejad, Nima (9)
Kim, Daniel (9)
Mensah, George A. (9)
Patton, George C. (9)
Rafay, Anwar (9)
Schutte, Aletta E. (9)
Tabares-Seisdedos, R ... (9)
Yano, Yuichiro (9)
visa färre...
Lärosäte
Karolinska Institutet (41)
Uppsala universitet (34)
Lunds universitet (31)
Umeå universitet (19)
Göteborgs universitet (17)
Chalmers tekniska högskola (13)
visa fler...
Högskolan Dalarna (12)
Stockholms universitet (11)
Linköpings universitet (6)
Örebro universitet (5)
Sveriges Lantbruksuniversitet (5)
Luleå tekniska universitet (3)
Mittuniversitetet (3)
Södertörns högskola (3)
Kungliga Tekniska Högskolan (2)
Handelshögskolan i Stockholm (2)
Linnéuniversitetet (2)
Högskolan i Halmstad (1)
Högskolan i Gävle (1)
Jönköping University (1)
Malmö universitet (1)
visa färre...
Språk
Engelska (82)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (59)
Naturvetenskap (27)
Samhällsvetenskap (6)
Teknik (3)
Lantbruksvetenskap (1)
Humaniora (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy